-
Information-Publications
-
A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPsDetails
-
SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitopeDetails
-
Engineered Extracellular Vesicle‐Delivered CRISPR/CasRx as a Novel RNA Editing ToolDetails
-
PHLDA1 suppresses TLR4-triggered proinflammatory cytokine production by interaction with tollipDetails
-
SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injuryDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands